Peptide Therapeutics
This article is a placeholder. Only its topic and title are committed at this stage; the substantive body will be drafted in a future cycle of the engine.
Short amino-acid sequences administered subcutaneously or orally — BPC-157, TB-500/TB-4, CJC-1295/ipamorelin (growth-hormone-axis), GHK-Cu (skin and inflammation), epitalon (telomere/pineal). The post-2023 FDA compounding-list changes reshaped what is legally available where, with several peptides now in regulatory limbo despite continued telemedicine availability.